Transcript CCI10slides.pps - Cardio Command

It’s right. Next to the Heart.
CardioCommand Mission
“As the inventor of DinamapTM 20 years ago, I believed
technology could make a real clinical contribution in the
noninvasive monitoring of arterial blood pressure. Today,
technology must also enable more efficient healthcare
delivery.”
CardioCommand has pioneered a new class of
noninvasive technology that can diagnose,
monitor and treat the heart.
Maynard (Mike) Ramsey, MD, PhD
CEO/CSO
More efficient healthcare.
Meeting a growing need
CardioCommand provides clinicians with
safer and faster treatment and diagnostic
options for achieving optimum heart rate. Its
technology combines safe heart rate control
with breakthrough monitoring parameters to
help minimize patient risk from known or
unrecognized heart disease in both acute care
and diagnostic settings.
More at-risk patients.
The Esophageal Window to the Heart
CardioCommand products exploit
the close anatomical proximity
between the esophagus and the left
atrium of the heart. Since
CardioCommand applications are
administered across the anterior
esophageal wall, they are referred to
as transesophageal, and hence are
noninvasive in their approach to
pacing (TAP) and monitoring.
CardioCommand
transesophageal
catheter
Atrium
Pacing and
recording
electrodes
Ventricle
Noninvasive, safe and efficient.
TAPSCOPE TM
. . . for perioperative hemodynamic management
TAP-all G3 patients responded
Study- 64 patients
70% became bradycardic
Study notes:
66% of G1 & 53% of G2
required 2nd drug dose

1 G2 required 3rd drug dose
& 1 G2 had no drug response
after 4 drug doses & was
treated successfully with TAP

Treatment groups: G1 15 pts atropine, G2 15 pts glycopyrrolate, G3 15 pts TAPSCOPE, 19 pts control & untreated
(Smith, Ian, et.al. Anesth Analg 1994;78:245-52)
Predictable heart rate control.
TAPSTRESS TM
. . . for non-exercise stress echocardiography
Faster Study Times


TM
100 patients comparing TAPSTRESS and Mayo standard dobutamine
stress echo protocol
RESULTS:
TAPSTRESSTM
dobutamine
-minutes: test+recovery 9.6
29.0
-achieved target HR
98 %
89 %
More Efficacious
-symptoms/dysrhythmias few
more
-wall motion concordance good
good
-labor intensity of test
less
greater
Greater Staff Efficiencies
Safer
*Lee, Pellikka, et al, Nonexercise Stress Transthoracic Echocardiography:
Transesophageal Atrial Pacing versus Dobutamine Stress. JACC, 1999;
33:506-11
Reimbursable, out-of-hospital testing.
TAPCATH
TM
. . . for electrophysiology & cardioversion
Cardioversion
of atrial flutter
using transesophageal
burst pacing
Transient atrial fibrillation before
conversion to sinus rhythm
Esophageal ECG
provides superior
atrial arrhythmia
information
No anesthesia, no intracardiac catheters.
Compelling and growing needs
• Esophageal
V lead connection
Perioperative MI
150,000 cases per year & 50,000 associated deaths
Chest Pain & Acute MI
8,000,000 chest pain ED visits per year & 500,000 deaths
Atrial Fibrillation
3,000,000 patients & leading cause of stroke
And the promise of a new approach.
About CardioCommand

CardioCommand has 9 products with FDA PMA approval for US
distribution and 29 issued US and International patents in the areas of
transesophaeal pacing and cardioversion.

Over 200 scientific articles have investigated & validated transesophageal
technology and applications

CardioCommand, Inc. operated as ARZCO Medical Systems, Inc. from 1994
until 1998

CardioCommand’s corporate headquarters are located in Tampa, Florida,
under the direction of Maynard (Mike) Ramsey, MD, PhD
World’s leader in transesophageal technology.
It’s right. Next to the Heart.